CD147 expression in pituitary adenomas and its significance for clinical outcome

Human Pathology

Volumn 41, Issue 8, 2010, Pages 1165-1171

  Qu, Xin ^a   Yang, Wei ^a   Jiang, Meng ^a   Han, Tao ^a   Han, Lizhang ^a   Qu, Yuanming ^a   Wang, Guodong ^a   Shi, Dongli ^a   Xu, Guangming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

CD147; MMP 2; Pituitary adenoma

Indexed keywords

CD147 ANTIGEN; GELATINASE A; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOMA; ADOLESCENT; BIOSYNTHESIS; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADENOMA; ADOLESCENT; ADULT; AGED; ANTIGENS, CD147; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; PITUITARY NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77955077879     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.10.023     Document Type: Article

References (33)

1. Asa S.L., and Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas Endocr Rev 19 1998 798 827
2. Hussaini I.M., Trotter C., and Zhao Y. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line Am J Pathol 170 2007 356 365
3. Gurlek A., Karavitaki N., Ansorge O., and Wass J.A. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156 2007 143 153
4. Tan H., Ye K., Wang Z., and Tang H. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma Transl Res 152 2008 143 149
5. Kawamoto H., Uozumi T., Kawamoto K., Arita K., Yano T., and Hirohata T. Collagenase activity and cavernous sinus invasion in human pituitary adenomas Acta Neurochir (Wien) 138 1996 390 395
6. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 2002 161 174
7. Reimers N., Zafrakas K., and Assmann V. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells Clin Cancer Res 10 2004 3422 3428
8. Zou W., Yang H., Hou X., Zhang W., Chen B., and Xin X. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells Cancer Lett 248 2007 211 218
9. Chen X., Lin J., Kanekura T., Su J., Lin W., and Xie H. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma Cancer Res 66 2006 11323 11330
10. Zhang W., Erkan M., and Abiatari I. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells Cancer Biol Ther 6 2007 218 227
11. Madigan M.C., Kingsley E.A., and Cozzi P.J. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression Cancer Immunol Immunother 57 2008 1367 1379
12. Zhang Q., Zhou J., and Ku X.M. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma Eur J Cancer Prev 16 2007 196 202
13. Li H., Chen J., He M., Hui X.H., Cai B.W., and Li Y. Expression of CD147 and MMP-2 in human gliomas and its correlations with prognosis Sichuan Da Xue Xue Bao Yi Xue Ban 38 2007 396 399
14. Ju X.Z., Yang J.M., Zhou X.Y., Li Z.T., and Wu X.H. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer Clin Cancer Res 14 2008 494 501
15. Zhong W.D., Han Z.D., He H.C., and Bi X.C. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer Oncology 75 2008 230 236
16. Qian Z.R., Asa S.L., and Siomi H. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas Mod Pathol 22 2009 431 441
17. Wu W., Wang R., and Liu H. Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry Med Oncol 26 2009 117 123
18. Riethdorf S., Reimers N., and Assmann V. High incidence of EMMPRIN expression in human tumors Int J Cancer 119 2006 1800 1810
19. Liu W.P., and Kunishio K. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas Journal of Clinical Neuroscience 12 2005 791 794 (Pubitemid 41411888)
20. Ellis S.M., Nabeshima K., and Biswas C. Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor Cancer Res 49 1989 3385 3391
21. Biswas C. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily Cancer Research 55 1995 434 439
22. Nabeshima K., Lane W.S., and Biswas C. Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor Arch Biochem Biophys 285 1991 90 96
23. Tang Y., Kesavan P., Nakada M.T., and Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN Mol Cancer Res 2 2004 73 80
24. Baba M., Inoue M., Itoh K., and Nishizawa Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism Biochemical and Biophysical Research Communications 374 2008 111 116
25. Su J., Chen X., and Kanekura T. A CD147-targeting siRNA inhibits the proliferation, invasiveness,and VEGF production of human malignant melanoma cells by down-regulating glycolysis Cancer Letters 273 2009 140 147
26. Kontogeorgos G. Classification and pathology of pituitary tumors Endocrine 28 2005 27 35
27. Knauper V., and Murphy G. Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases Matrix Metalloproteinases 1998 199 218
28. Turner H.E., Nagy Z., Esiri M.M., Harris A.L., and Wass J.A. Role of matrix metalloproteinase 9 in pituitary tumor behavior J Clin Endocrinol Metab 85 2000 2931 2935
29. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview Mol Cell Biochem 253 2003 269 285
30. Peker S., Kurtkaya-Yapicier O., Kilic T., and Pamir M.N. Microsurgical anatomy of the lateral walls of the pituitary fossa Acta Neurochir (Wien) 147 2005 641 648 discussion 649
31. Murphy G., and Nagase H. Progress in matrix metalloproteinase research Mol Aspects Med 29 2008 290 308
32. Liu W.P., Matsumoto Y., and Okada M. Matrix metalloproteinase-2 and-9 expression correlated with cavernous sinus invasion of pituitary adenomas J Med Invest 52 2005 151 158 (Pubitemid 41602589)
33. Meij B.P., Lopes M.B., Ellegala D.B., Alden T.D., and Laws E.R. Jr The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery J Neurosurg 96 2002 195 208